PMC:7060195 / 3871-5297 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"99","span":{"begin":676,"end":677},"obj":"Gene"},{"id":"100","span":{"begin":680,"end":688},"obj":"Gene"},{"id":"101","span":{"begin":690,"end":691},"obj":"Gene"},{"id":"102","span":{"begin":708,"end":709},"obj":"Gene"},{"id":"103","span":{"begin":716,"end":721},"obj":"Gene"},{"id":"104","span":{"begin":723,"end":724},"obj":"Gene"},{"id":"105","span":{"begin":820,"end":823},"obj":"Gene"},{"id":"106","span":{"begin":825,"end":828},"obj":"Gene"},{"id":"107","span":{"begin":694,"end":706},"obj":"Gene"},{"id":"108","span":{"begin":24,"end":34},"obj":"Species"},{"id":"109","span":{"begin":273,"end":283},"obj":"Species"},{"id":"110","span":{"begin":305,"end":313},"obj":"Species"},{"id":"111","span":{"begin":318,"end":373},"obj":"Species"},{"id":"112","span":{"begin":617,"end":627},"obj":"Species"},{"id":"113","span":{"begin":977,"end":986},"obj":"Disease"},{"id":"114","span":{"begin":77,"end":87},"obj":"CellLine"},{"id":"115","span":{"begin":89,"end":99},"obj":"CellLine"},{"id":"116","span":{"begin":114,"end":124},"obj":"CellLine"},{"id":"117","span":{"begin":126,"end":136},"obj":"CellLine"},{"id":"118","span":{"begin":138,"end":148},"obj":"CellLine"},{"id":"119","span":{"begin":150,"end":160},"obj":"CellLine"},{"id":"120","span":{"begin":162,"end":172},"obj":"CellLine"},{"id":"121","span":{"begin":174,"end":184},"obj":"CellLine"},{"id":"122","span":{"begin":186,"end":196},"obj":"CellLine"},{"id":"123","span":{"begin":202,"end":212},"obj":"CellLine"}],"attributes":[{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Gene:43740570"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Gene:43740571"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Gene:43740571"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"Gene:43740575"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Gene:43740568"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"Gene:43740568"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"Gene:920"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"Gene:925"},{"id":"A107","pred":"tao:has_database_id","subj":"107","obj":"Gene:43740575"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"Tax:2697049"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"Tax:2697049"},{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"Tax:694009"},{"id":"A111","pred":"tao:has_database_id","subj":"111","obj":"Tax:1335626"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"Tax:2697049"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:D056486"},{"id":"A114","pred":"tao:has_database_id","subj":"114","obj":"CVCL:U508"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"CVCL:U508"},{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"CVCL:U508"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"CVCL:U508"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"CVCL:U508"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"CVCL:U508"},{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"CVCL:U508"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"CVCL:U508"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"CVCL:U508"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"CVCL:U508"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":35,"end":42},"obj":"Body_part"},{"id":"T8","span":{"begin":422,"end":425},"obj":"Body_part"},{"id":"T9","span":{"begin":439,"end":445},"obj":"Body_part"},{"id":"T10","span":{"begin":464,"end":475},"obj":"Body_part"},{"id":"T11","span":{"begin":648,"end":656},"obj":"Body_part"},{"id":"T12","span":{"begin":739,"end":747},"obj":"Body_part"},{"id":"T13","span":{"begin":832,"end":836},"obj":"Body_part"},{"id":"T14","span":{"begin":1091,"end":1094},"obj":"Body_part"},{"id":"T15","span":{"begin":1099,"end":1103},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma67122"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":977,"end":986},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":24,"end":32},"obj":"Disease"},{"id":"T24","span":{"begin":273,"end":281},"obj":"Disease"},{"id":"T25","span":{"begin":305,"end":313},"obj":"Disease"},{"id":"T26","span":{"begin":617,"end":625},"obj":"Disease"},{"id":"T27","span":{"begin":977,"end":988},"obj":"Disease"},{"id":"T28","span":{"begin":977,"end":986},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005344"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T24","span":{"begin":243,"end":248},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T25","span":{"begin":426,"end":431},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T26","span":{"begin":437,"end":438},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T27","span":{"begin":608,"end":609},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":628,"end":631},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T29","span":{"begin":680,"end":688},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T30","span":{"begin":820,"end":823},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T31","span":{"begin":825,"end":828},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T32","span":{"begin":830,"end":836},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T33","span":{"begin":987,"end":988},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T34","span":{"begin":1066,"end":1072},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":464,"end":475},"obj":"Chemical"},{"id":"T10","span":{"begin":648,"end":656},"obj":"Chemical"},{"id":"T11","span":{"begin":739,"end":747},"obj":"Chemical"},{"id":"T12","span":{"begin":761,"end":769},"obj":"Chemical"},{"id":"T13","span":{"begin":921,"end":930},"obj":"Chemical"},{"id":"T14","span":{"begin":997,"end":1004},"obj":"Chemical"},{"id":"T15","span":{"begin":1091,"end":1094},"obj":"Chemical"},{"id":"T16","span":{"begin":1364,"end":1372},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T7","span":{"begin":546,"end":555},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}

{"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":272},"obj":"Sentence"},{"id":"T30","span":{"begin":273,"end":607},"obj":"Sentence"},{"id":"T31","span":{"begin":608,"end":728},"obj":"Sentence"},{"id":"T32","span":{"begin":729,"end":850},"obj":"Sentence"},{"id":"T33","span":{"begin":851,"end":1086},"obj":"Sentence"},{"id":"T34","span":{"begin":1087,"end":1205},"obj":"Sentence"},{"id":"T35","span":{"begin":1206,"end":1303},"obj":"Sentence"},{"id":"T36","span":{"begin":1304,"end":1426},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8."}